Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Rhea-AI Summary
Dogwood Therapeutics (NASDAQ: DWTX) announced registered and private offerings to raise up to $12.5 million in upfront gross proceeds and the potential for an additional $14.4 million upon warrant exercises, for aggregate financings tied to issuance of 4,386,037 common shares (or pre-funded warrants) and detachable warrants. Securities are priced at-the-market under Nasdaq rules at a combined purchase price of $2.85 and warrant exercise price of $3.28. Proceeds are earmarked to advance Halneuron through Phase 2b final readout and support further development and working capital.
Positive
- Upfront gross proceeds of $12.5M
- Potential additional $14.4M upon warrant exercise
- Financing explicitly to advance Halneuron Phase 2b and Phase 3 planning
- Registered offering uses an effective Form S-3 shelf registration
Negative
- Issuance of 4,386,037 shares and warrants will dilute existing shareholders
- Warrants exercisable only upon shareholder approval, delaying potential cash
- Combined purchase price of $2.85 signals capital raised at current depressed level
News Market Reaction – DWTX
In the Jan 12 session, DWTX gained 5.61%, reflecting a notable positive market reaction. Argus tracked a peak move of +16.8% during that session. Argus tracked a trough of -5.9% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 22 | Clinical trial update | Positive | -25.0% | Positive interim Phase 2b data for Halneuron in chemotherapy neuropathic pain. |
| Dec 02 | IP / exclusivity | Positive | -2.0% | New synthetic Halneuron IP filing projected to extend exclusivity to 2045. |
| Nov 11 | Trial enrollment | Positive | +1.4% | First 100 patients enrolled in Halneuron Phase 2b HALT-CINP trial. |
| Nov 06 | Earnings update | Negative | -6.5% | Q3 2025 loss of $15.7M and cash runway only through Q1 2026. |
| Oct 30 | Earnings date notice | Neutral | +7.8% | Announcement of timing for upcoming Q3 2025 financial results release. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows multiple positive clinical and IP updates followed by negative price reactions, while more clearly negative financial news has also led to share price weakness.
Over the past few months, Dogwood reported several key milestones. On Oct 30, 2025, it scheduled Q3 results, followed by Q3 earnings on Nov 6, 2025 showing a net loss of $15.7M and cash of $10.1M with runway into Q1 2026. Subsequent Halneuron® updates included first 100 patients enrolled in Phase 2b and a positive interim analysis from 97 patients. A synthetic Halneuron IP filing projected potential exclusivity to 2045. Despite these developments, shares often reacted negatively to ostensibly positive news, framing today’s financing against a backdrop of prior volatility and funding needs.
Key Terms
registered direct offering financial
private placement financial
pre-funded warrants financial
warrants financial
form s-3 regulatory
prospectus supplement regulatory
section 4(a)(2) regulatory
regulation d regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
| Pricing of |
| Offerings priced at-the-market under Nasdaq rules |
ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately
The Registered Offering consists of the issuance and sale of 2,338,948 shares of common stock, and the Private Offering consists of the issuance and sale of pre-funded warrants to purchase 2,047,089 shares of common stock and warrants to purchase up to 4,386,037 shares of common stock.
Greg Duncan, Chairman and CEO of DWTX, commented: “We plan to utilize the net proceeds from the Offering to advance development of Halneuron® through the ongoing Phase 2b final data readout, while also pursuing strategic opportunities to further strengthen the Company’s research portfolio. We are executing with determination to advance the standard of care for patients suffering from chemotherapy induced pain and neuropathy, conditions for which there are no FDA approved treatments. This transaction represents a strong endorsement of our two first-in-class development candidates, Halneuron® and SP16, our research progress, growing IP portfolio and the exceptional talent we’ve assembled. Today’s offering provides DWTX with access to additional capital to support Phase 3 development.”
Maxim Group LLC is acting as the sole placement agent for the Offerings.
The Company intends to use the net proceeds from this offering to further advance the clinical development of Halneuron® and for working capital and general corporate purposes. The Offerings are expected to close on or about January 13, 2026 (the “Closing Date”), subject to the satisfaction of customary closing conditions.
The Registered Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-287575) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on June 2, 2025. The Registered Offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the effective shelf registration statement. A prospectus supplement relating to the shares of common stock to be issued in the Registered Offering will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the Registered Offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or by telephone at (212) 895-3745.
The pre-funded warrants and warrants described above were offered in a private placement under Section 4(a)(2) of the Act and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Pursuant to a securities purchase agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock issuable upon exercise of the pre-funded warrants and warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Dogwood Therapeutics
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV. Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (LRP1) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CINP trial is fully funded by the National Cancer Institute.
Dogwood Therapeutic’s largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.
Forward-Looking Statements:
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and consummation of the Offerings, and the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.
Investor Relations:
CORE IR
(516) 222-2560
IR@dwtx.com
